Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00199069
Other study ID # GMALL09
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 1993
Est. completion date May 2001

Study information

Verified date March 2023
Source Goethe University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study evaluates the efficacy and tolerability of a risk- and subtype-adapted chemotherapy over one year, followed by randomized either intensified or conventional maintenance therapy. It includes a distinct protocol for the subgroup 'mature B-ALL',


Recruitment information / eligibility

Status Completed
Enrollment 720
Est. completion date May 2001
Est. primary completion date January 1999
Accepts healthy volunteers No
Gender All
Age group 15 Years to 65 Years
Eligibility Inclusion Criteria: - Acute Lymphocytic Leukemia - Age 15 - 65 years Exclusion Criteria: - Serious secondary diseases which may compromise intensified chemotherapeutical treatment - Serious psychiatric diseases, which may compromise compliance with therapy - HIV-1 or HIV-2 Infection - Pretreatment > 2 weeks or chemotherapy other than Vincristine and Steroids - Patients without central diagnosis who cannot be allocated to a risk group

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Asparaginase

Vincristine

Daunorubicin, Adriamycin

Cyclophosphamide

Ifosfamide

Cytarabine

Mitoxantrone

Methotrexate

6-Mercaptopurine

6-Thioguanine

VM26

Dexamethasone / Prednisolone

Procedure:
CNS Irradiation

Mediastinal Irradiation

Stem Cell Transplantation


Locations

Country Name City State
Germany University Hospital, Medical Dept. II Frankfurt

Sponsors (2)

Lead Sponsor Collaborator
Goethe University Deutsche Krebshilfe e.V., Bonn (Germany)

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary remission rate, disease free survival, overall survival
Secondary death in induction, toxicity, time and dose compliance
See also
  Status Clinical Trial Phase
Completed NCT00199056 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Phase 4
Completed NCT00199043 - Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Phase 3
Completed NCT00198978 - German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase 4
Completed NCT00199095 - Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Phase 4
Completed NCT00199004 - Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Phase 4
Completed NCT00199108 - Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Phase 2/Phase 3
Completed NCT00198991 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Phase 4